# Sernova and Seraxis close USD 11.2 million financing for cell therapy trial

_Published Monday, October 5, 2026 at 1:18 PM EDT · Science, Capital · Latest · Tier 2 — Notable_

![Sernova and Seraxis close USD 11.2m financing to advance merger and T1D cell therapy trial — Primary](https://allsci.com/og/article/news/biotech/sernova-financing-and-seraxis-close-usd-112m-to.png)

Sernova Biotherapeutics and Seraxis Holdings have closed USD 11.2 million in financing to support their proposed merger into BetaNova Biotherapeutics and clinical testing of SR-02, a pancreatic islet cell therapy for type 1 diabetes.

The financing exceeded a USD 10 million target. Proceeds are expected to support manufacturing, patient enrollment beginning in Q4 2026 and first dosing in a Phase I/II study in Q1 2027 under an FDA-cleared investigational new drug application. Initial clinical data are expected in H1 2027.

## Sources

- [allsci.com](https://allsci.com/news/biotech/sernova-financing-and-seraxis-close-usd-112m-to/)

---
Canonical: https://techandbusiness.org/newswire/yY7kflc-nZTHkgRjuPK5ao
Published: 2026-10-05T17:18:52.328Z
Story chronology: 2026-10-05T16:15:22.377Z
Retrieved: 2026-10-05T19:17:27.049Z
Publisher: Tech & Business (techandbusiness.org)